biostudies-literatureUnknown39Perez-Martinez A<h4>Background</h4>Effective treatments are still needed to reduce the severity of symptoms, time of hospitalization, and mortality of COVID-19. SARS-CoV-2 specific memory T-lymphocytes obtained from convalescent donors recovered can be used as passive cell immunotherapy.<h4>Methods</h4>Between September and November 2020 a phase 1, dose-escalation, single centre clinical trial was conducted to evaluate the safety and feasibility of the infusion of CD45RA^- memory T cells containing SARS-CoV-2 specific T cells as adoptive cell therapy against moderate/severe cases of COVID-19. Nine participants with pneumonia and/or lymphopenia and with at least one human leukocyte antigen (HLA) match with the donor were infused. The first three subjects received the lowest dose (1 × 10<sup>5</suEClinicalMedicine101086https://www.ebi.ac.uk/biostudies/studies/S-EPMC8361305biostudies-literaturePhase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE).PMC8361305Sanchez-Zapardiel EBalas ABuckley RMGuerra-Garcia PMoreno MAArribas JRGasior MMora-Rillo MDe Paz RVicario JLPerez-Martinez APascual-Miguel BQueiruga-Parada JMarcos AFerreras CGarcia IEguizabal CMestre-Duran CCarcas AJMontejano RSoria BBorobia AMSolano CfalsePhase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE).<h4>Background</h4>Effective treatments are still needed to reduce the severity of symptoms, time of hospitalization, and mortality of COVID-19. SARS-CoV-2 specific memory T-lymphocytes obtained from convalescent donors recovered can be used as passive cell immunotherapy.<h4>Methods</h4>Between September and November 2020 a phase 1, dose-escalation, single centre clinical trial was conducted to evaluate the safety and feasibility of the infusion of CD45RA^- memory T cells containing SARS-CoV-2 specific T cells as adoptive cell therapy against moderate/severe cases of COVID-19. Nine participants with pneumonia and/or lymphopenia and with at least one human leukocyte antigen (HLA) match with the donor were infused. The first three subjects received the lowest dose (1 × 10<sup>5</su2021-01-01T00:00:00Z2021 Sep2026-05-09T03:25:53.735Z2022-02-11T11:20:45.721ZS-EPMC83613053440514010.1016/j.eclinm.2021.101086